News & Updates
Filter by Specialty:
How does IV edaravone fare for ALS in the real world?
Intravenous (IV) edaravone seems to continue to provide hope for individuals with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease with no known cure, according to data presented at AAN 2022.
How does IV edaravone fare for ALS in the real world?
10 May 2022
Trabectedin–durvalumab combo shows antitumour activity in refractory ovarian carcinoma
Combination treatment with trabectedin and durvalumab appears to be promising in the treatment of patients with platinum-refractory ovarian carcinoma, shrinking tumour while having a manageable side effect profile, according to data from the phase Ib TRAMUNE trial.
Trabectedin–durvalumab combo shows antitumour activity in refractory ovarian carcinoma
10 May 2022
New chemo-free triplet regimen shows promise for endometrial cancer
A triplet regimen combining the PARP inhibitor olaparib with metronomic cyclophosphamide and metformin showed favourable signals for heavily pretreated women with advanced endometrial carcinoma, the phase I/II ENDOLA study suggests.
New chemo-free triplet regimen shows promise for endometrial cancer
09 May 2022
First-line camrelizumab-chemo combo boosts OS in advanced squamous NSCLC
Treatment comprising camrelizumab, carboplatin, and paclitaxel in the first-line setting improved overall survival (OS) in patients with advanced squamous non-small-cell lung cancer (NSCLC), according to updated results of the phase III CameL-sq trial from China.